Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: Pillar Biosciences partnered with AstraZeneca to improve access to rapid and affordable liquid biopsy NGS testing for cancer in Europe and the UK. Neurocrine Biosciences is set to present at the 2024 Cantor Global Healthcare Conference on September 17 at 3:05 p.m. Eastern Time.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
